“Building a profile and becoming ‘known’ is a critical part of raising money…” — Erin Righetti, partnering360®

Healthcare conferences are in full swing this week in San Francisco, with attendees from companies large and small making the circuit at J.P. Morgan’s Annual Healthcare Conference, the EBD Group’s annual Biotech Showcase™, the StartUp Health Festival, and many others. From corporate presentations to strategic one-on-one meetings and even impromptu run-ins, networking opportunities abound and it is important for CEOs to be able to quickly, concisely, and effectively pitch their company to potential investors and/or partners.

An Executive Informational Overview (EIO) is now available on the medical device company Aperion Biologics, Inc. The EIO released Friday is a 60-page report detailing Aperion's business, technology and product development, market opportunities, competition, financials, risks, and more. It is available for download below.

In just six months, drug companies have spent $221 billion buying each other, with a lot of recent mergers being between biotech firms. So what is driving the deals? Business television show Arise Xchange sits down with Jeff Kraws, Cofounder and CEO of Crystal Research Associates, to discuss. 

Runtime: 3:38 minutes

One of the most recent revolutions in healthcare is the role of Big Data. An article published on CNBC this morning noted how much data is being collected related to patient care today, from doctors digitizing patient records to the patients themselves who monitor “their activity, sleep and calorie burn using fitness trackers.” Pharma companies have been building medical databases comprising years of R&D data, augmented by clinical trial and insurance program data from government and other public sources (Source: McKinsey & Company). Patient-specific data is today available from multiple sources, including insurance payors, hospitals, laboratories, physicians’ offices, remote monitoring systems, and uploaded by patients directly through health and wellness apps and connected devices. Bernard Marr, a Forbes contributor, writes

Aeterna Zentaris Inc. (AEZS) (TSX: AEZ) today announced that its lead oncology compound, zoptarelin doxorubicin (formerly AEZS‑108), met the primary endpoint of the investigator-driven and sponsored Phase 2 clinical trial in Castration- and Taxane-Resistant Prostate Cancer (CRPC) and demonstrated good tolerability. The primary endpoint was Clinical Benefit (CB) defined as remaining progression-free by RECIST and Prostate Specific Antigen (PSA) after treatment for 12+ weeks.

Crystal Research Associates has released a slide presentation on Catasys, Inc. (CATS-OTC) to summarize major facets of Catasys' treatment program, value proposition for health insurance providers, and market opportunities, as presented in greater detail in the 56-page Executive Informational Overview available for download here.

Crystal Research Associates has released a 56-page Executive Informational Overview (EIO) on healthcare service and data analytics company, California-based Catasys, Inc. The EIO details Catasys' business model, technology development, customers and end users, treatment approach, opportunities in the behavioral healthcare market, competition, and more. The report is available for download below.

Crystal Research Associates announces the publication of an Executive Informational Overview (EIO) on SpectraScience, Inc. (SCIE-OTC), a company commercializing advanced, minimally invasive diagnostic products. The 48-page EIO, which details SpectraScience's business, technology and product development, clinical studies, manufacturing, market opportunities, competition, and more, is available for download below.

We published a 12-page Quarterly Update on specialty biopharmaceutical company Aeterna Zentaris, Inc. this morning. The report updates readers on Aeterna's news, milestones, and clinical and commercial development status since the publication of our base report, the Executive Informational Overview from April 2015.

• Data show that MABp1 has led to rapid improvement in skin lesions and acne-associated psychological symptoms.

• Findings are published in the June 2015 issue of Journal of Drugs in Dermatology. (J Drugs Dermatol. June 2015;14(6):560-564)

Crystal Research Associates has released a slide presentation on Aeterna Zentaris Inc. (AEZS-NASDAQ; AEZ-TSX) to summarize major facets of Aeterna's product development and key milestones, as presented in greater detail in the 52-page Executive Informational Overview available for download here. 

Crystal Research Associates has released a slide presentation on Juhl Energy, Inc. (JUHL-OTC) to summarize major facets of Juhl's business and markets, as detailed in the 56-page Executive Informational Overview available for download here. 

Crystal Research Associates has released a new Executive Informational Overview (EIO) on XBiotech Inc. (XBIT-NASDAQ), a company engaged in discovering, developing, and translating natural human immunity into novel therapeutic antibody products. The 60-page EIO, which details XBiotech's business, technology and product development, manufacturing expertise, market opportunities, competition, and more, is available for download below.

Specialty biopharmaceutical company Aeterna Zentaris Inc. (AEZS-NASDAQ; AEZ-TSX) announced this morning that it has entered into a promotional services agreement with EMD Serono, Inc., the U.S. and Canadian biopharmaceutical businesses of Merck KGaA (MRK-NYSE). Under the agreement, Aeterna can begin promoting Saizen® [somatropin (rDNA origin) for injection] to designated medical professionals in specified territories in the U.S. Aeterna will work within the realm of field promotion of Saizen® by driving awareness of the product among medical professionals, and expects to be compensated on the basis of new, eligible patient starts on Saizen® above an agreed-upon baseline. This is the second promotional services agreement for Aeterna in recent months, as the company accelerates its transition into a commercially operating specialty biopharma by leveraging its sales force.

• Amarantus Receives Notice of Allowance for U.S. Patent Application Covering Proprietary Compositions of Matter and Methods of Use for MANF

• Patent Issuance Will Provide Additional IP Protection for MANF Protein Therapy and Cell Therapy

SAN FRANCISCO and GENEVA, May 5, 2015 (GLOBE NEWSWIRE) -- Amarantus BioScience Holdings, Inc. (AMBS), a biotechnology company focused on developing therapeutic and diagnostic products for neurological disorders and orphan indications, announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for U.S. Patent Application Serial No. 13/305,025 entitled, "Dopaminergic Neuronal Survival Promoting Factors and Uses Thereof." Upon issuance, the patent will provide additional intellectual property protection for MANF (mesencephalic-astrocyte-derived neurotrophic factor) protein therapy and cell therapy. The allowed patent claims cover compositions of matter and methods of use related to the Company's proprietary manufacturing process for synthetic MANF and its administration.